DETECT-ATTR AI echocardiography study with a California health system
Diagnostics and clinical decision support Announcement
Disclosed: Verified:
In its second-quarter 2026 results, Alnylam said it had announced a collaboration with a large health care system in California to support that system's DETECT-ATTR study. The study evaluates Invision Precision Cardiac Amyloid, described as an AI-enabled, FDA-cleared echocardiography screening approach for cardiac amyloidosis.
Source
Company Archive pending